Dr Judith Marie Gilbreth, MD | |
2434 Harville Rd, Suite 101, Duncan, OK 73533 | |
(580) 252-1918 | |
(580) 252-2333 |
Full Name | Dr Judith Marie Gilbreth |
---|---|
Gender | Female |
Speciality | Family Practice |
Experience | 33 Years |
Location | 2434 Harville Rd, Duncan, Oklahoma |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1407823982 | NPI | - | NPPES |
232803801 | Other | OK | MEDICARE PROVIDER NUMBER |
OK700276 | Other | OK | MEDICARE INDIVIDUAL PTAN |
100170200C | Other | OK | SOONERCARE PROVIDER NUMBE |
100170200B | Medicaid | OK |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 19187 (Oklahoma) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Health Watch Health Care Of Duncan, Llc | Duncan, OK | Home health agency |
Duncan Regional Hospital Homecare | Duncan, OK | Home health agency |
Elara Caring Iv | Chickasha, OK | Home health agency |
Duncan Regional Hospital, Inc | Duncan, OK | Hospital |
Entity Name | Gilbreth Family Medicine, Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1689843997 PECOS PAC ID: 3274601521 Enrollment ID: O20081014000292 |
News Archive
An article published in Frontiers in Immunology suggests that sepsis can cause alterations in the functioning of defense cells that persist even after the patient is discharged from hospital.
A study recently published in the Journal of the American Academy of Dermatology shows that for Ebola, measles, syphilis and many other conditions with skin manifestations the mortality rates are hundreds of times higher in developing countries than they are in developed countries.
Most dialysis patients are not prepared to effectively handle man-made or natural disasters, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for the subcutaneous formulation of ORENCIA® (abatacept), a treatment for adult patients with moderate to severe rheumatoid arthritis (RA) administered through an injection into the skin. Bristol-Myers Squibb submitted the sBLA to the FDA for the subcutaneous formulation of ORENCIA and received confirmation of its receipt on October 4, 2010.
› Verified 4 days ago
Entity Name | Hcc Duncan Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1013153543 PECOS PAC ID: 1759447873 Enrollment ID: O20090225000497 |
News Archive
An article published in Frontiers in Immunology suggests that sepsis can cause alterations in the functioning of defense cells that persist even after the patient is discharged from hospital.
A study recently published in the Journal of the American Academy of Dermatology shows that for Ebola, measles, syphilis and many other conditions with skin manifestations the mortality rates are hundreds of times higher in developing countries than they are in developed countries.
Most dialysis patients are not prepared to effectively handle man-made or natural disasters, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for the subcutaneous formulation of ORENCIA® (abatacept), a treatment for adult patients with moderate to severe rheumatoid arthritis (RA) administered through an injection into the skin. Bristol-Myers Squibb submitted the sBLA to the FDA for the subcutaneous formulation of ORENCIA and received confirmation of its receipt on October 4, 2010.
› Verified 4 days ago
Entity Name | Duncan Regional Hospital, Inc. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1699318147 PECOS PAC ID: 5193613057 Enrollment ID: O20200930003440 |
News Archive
An article published in Frontiers in Immunology suggests that sepsis can cause alterations in the functioning of defense cells that persist even after the patient is discharged from hospital.
A study recently published in the Journal of the American Academy of Dermatology shows that for Ebola, measles, syphilis and many other conditions with skin manifestations the mortality rates are hundreds of times higher in developing countries than they are in developed countries.
Most dialysis patients are not prepared to effectively handle man-made or natural disasters, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for the subcutaneous formulation of ORENCIA® (abatacept), a treatment for adult patients with moderate to severe rheumatoid arthritis (RA) administered through an injection into the skin. Bristol-Myers Squibb submitted the sBLA to the FDA for the subcutaneous formulation of ORENCIA and received confirmation of its receipt on October 4, 2010.
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Judith Marie Gilbreth, MD 2434 Harville Rd, Suite 101, Duncan, OK 73533 Ph: (580) 252-1918 | Dr Judith Marie Gilbreth, MD 2434 Harville Rd, Suite 101, Duncan, OK 73533 Ph: (580) 252-1918 |
News Archive
An article published in Frontiers in Immunology suggests that sepsis can cause alterations in the functioning of defense cells that persist even after the patient is discharged from hospital.
A study recently published in the Journal of the American Academy of Dermatology shows that for Ebola, measles, syphilis and many other conditions with skin manifestations the mortality rates are hundreds of times higher in developing countries than they are in developed countries.
Most dialysis patients are not prepared to effectively handle man-made or natural disasters, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for the subcutaneous formulation of ORENCIA® (abatacept), a treatment for adult patients with moderate to severe rheumatoid arthritis (RA) administered through an injection into the skin. Bristol-Myers Squibb submitted the sBLA to the FDA for the subcutaneous formulation of ORENCIA and received confirmation of its receipt on October 4, 2010.
› Verified 4 days ago
Dan F Criswell, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2601 W Elk Ave, Duncan, OK 73533 Phone: 580-251-6644 Fax: 580-251-6645 | |
Krystal Marie Vonfeldt, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2120 W Elk Ave, Duncan, OK 73533 Phone: 580-251-6822 | |
William T Stewart, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1324 N Harville Rd, Duncan, OK 73533 Phone: 580-252-1373 Fax: 580-252-8336 | |
Francis James Mcgouran Iii, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1334 N Harville Rd, Duncan, OK 73533 Phone: 580-255-8564 Fax: 580-255-8640 | |
Demetra G Cox, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1324 N Harville Rd, Duncan, OK 73533 Phone: 580-252-1373 Fax: 580-252-8336 | |
Preston A Waters, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1324 N Harville Rd, Duncan, OK 73533 Phone: 580-252-1373 | |
Dr. Mark Rosekelly, D.O Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 4086 Country Club Rd Ste 2, Duncan, OK 73533 Phone: 580-952-9221 |